These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 28686671)

  • 41. Tumor-specific genetic aberrations in cell-free DNA of gastroesophageal cancer patients.
    Koldby KM; Mortensen MB; Detlefsen S; Pfeiffer P; Thomassen M; Kruse TA
    J Gastroenterol; 2019 Feb; 54(2):108-121. PubMed ID: 30242476
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinicopathologic Characteristics of HER2-positive Metastatic Colorectal Cancer and Detection of HER2 in Plasma Circulating Tumor DNA.
    Wei Q; Zhang Y; Gao J; Li J; Li J; Li Y; Zhou J; Lu M; Gong J; Zhang X; Shen L; Sun Y; Chang L; Wang X
    Clin Colorectal Cancer; 2019 Sep; 18(3):175-182. PubMed ID: 31227437
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genetic profiling of cancer with circulating tumor DNA analysis.
    Lu L; Bi J; Bao L
    J Genet Genomics; 2018 Feb; 45(2):79-85. PubMed ID: 29502957
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Methylated circulating tumor DNA in blood: power in cancer prognosis and response.
    Warton K; Mahon KL; Samimi G
    Endocr Relat Cancer; 2016 Mar; 23(3):R157-71. PubMed ID: 26764421
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cell-Free DNA as a Diagnostic Blood-Based Biomarker for Colorectal Cancer: A Systematic Review.
    Petit J; Carroll G; Gould T; Pockney P; Dun M; Scott RJ
    J Surg Res; 2019 Apr; 236():184-197. PubMed ID: 30694754
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cell-free DNA as a post-treatment surveillance strategy: current status.
    Burgener JM; Rostami A; De Carvalho DD; Bratman SV
    Semin Oncol; 2017 Oct; 44(5):330-346. PubMed ID: 29580435
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA.
    Parpart-Li S; Bartlett B; Popoli M; Adleff V; Tucker L; Steinberg R; Georgiadis A; Phallen J; Brahmer J; Azad N; Browner I; Laheru D; Velculescu VE; Sausen M; Diaz LA
    Clin Cancer Res; 2017 May; 23(10):2471-2477. PubMed ID: 27827317
    [No Abstract]   [Full Text] [Related]  

  • 48. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?
    Asante DB; Calapre L; Ziman M; Meniawy TM; Gray ES
    Cancer Lett; 2020 Jan; 468():59-71. PubMed ID: 31610267
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Considerations for the use of circulating tumor DNA sequencing as a screening tool in cancer predisposition syndromes.
    Paramathas S; Guha T; Pugh TJ; Malkin D; Villani A
    Pediatr Blood Cancer; 2020 Dec; 67(12):e28758. PubMed ID: 33047872
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Circulating tumor DNA outperforms circulating tumor cells for KRAS mutation detection in thoracic malignancies.
    Freidin MB; Freydina DV; Leung M; Montero Fernandez A; Nicholson AG; Lim E
    Clin Chem; 2015 Oct; 61(10):1299-304. PubMed ID: 26272233
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of circulating tumor DNA in the management of early-stage lung cancer.
    Zhao H; Chen KZ; Hui BG; Zhang K; Yang F; Wang J
    Thorac Cancer; 2018 May; 9(5):509-515. PubMed ID: 29528556
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multimodal analysis of methylomics and fragmentomics in plasma cell-free DNA for multi-cancer early detection and localization.
    Nguyen VTC; Nguyen TH; Doan NNT; Pham TMQ; Nguyen GTH; Nguyen TD; Tran TTT; Vo DL; Phan TH; Jasmine TX; Nguyen VC; Nguyen HT; Nguyen TV; Nguyen THH; Huynh LAK; Tran TH; Dang QT; Doan TN; Tran AM; Nguyen VH; Nguyen VTA; Ho LMQ; Tran QD; Pham TTT; Ho TD; Nguyen BT; Nguyen TNV; Nguyen TD; Phu DTB; Phan BHH; Vo TL; Nai THT; Tran TT; Truong MH; Tran NC; Le TK; Tran THT; Duong ML; Bach HPT; Kim VV; Pham TA; Tran DH; Le TNA; Pham TVN; Le MT; Vo DH; Tran TMT; Nguyen MN; Van TTV; Nguyen AN; Tran TT; Tran VU; Le MP; Do TT; Phan TV; Nguyen HL; Nguyen DS; Cao VT; Do TT; Truong DK; Tang HS; Giang H; Nguyen HN; Phan MD; Tran LS
    Elife; 2023 Oct; 12():. PubMed ID: 37819044
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment.
    Widman AJ; Shah M; Frydendahl A; Halmos D; Khamnei CC; Øgaard N; Rajagopalan S; Arora A; Deshpande A; Hooper WF; Quentin J; Bass J; Zhang M; Langanay T; Andersen L; Steinsnyder Z; Liao W; Rasmussen MH; Henriksen TV; Jensen SØ; Nors J; Therkildsen C; Sotelo J; Brand R; Schiffman JS; Shah RH; Cheng AP; Maher C; Spain L; Krause K; Frederick DT; den Brok W; Lohrisch C; Shenkier T; Simmons C; Villa D; Mungall AJ; Moore R; Zaikova E; Cerda V; Kong E; Lai D; Malbari MS; Marton M; Manaa D; Winterkorn L; Gelmon K; Callahan MK; Boland G; Potenski C; Wolchok JD; Saxena A; Turajlic S; Imielinski M; Berger MF; Aparicio S; Altorki NK; Postow MA; Robine N; Andersen CL; Landau DA
    Nat Med; 2024 Jun; 30(6):1655-1666. PubMed ID: 38877116
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Liquid biopsies come of age: towards implementation of circulating tumour DNA.
    Wan JCM; Massie C; Garcia-Corbacho J; Mouliere F; Brenton JD; Caldas C; Pacey S; Baird R; Rosenfeld N
    Nat Rev Cancer; 2017 Apr; 17(4):223-238. PubMed ID: 28233803
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Circulating Tumor DNA Assays in Clinical Cancer Research.
    Ossandon MR; Agrawal L; Bernhard EJ; Conley BA; Dey SM; Divi RL; Guan P; Lively TG; McKee TC; Sorg BS; Tricoli JV
    J Natl Cancer Inst; 2018 Sep; 110(9):929-934. PubMed ID: 29931312
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use of cell free DNA in breast oncology.
    Canzoniero JV; Park BH
    Biochim Biophys Acta; 2016 Apr; 1865(2):266-74. PubMed ID: 27012505
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of Circulating Tumor DNA for the Early Detection of Small-cell Lung Cancer.
    Fernandez-Cuesta L; Perdomo S; Avogbe PH; Leblay N; Delhomme TM; Gaborieau V; Abedi-Ardekani B; Chanudet E; Olivier M; Zaridze D; Mukeria A; Vilensky M; Holcatova I; Polesel J; Simonato L; Canova C; Lagiou P; Brambilla C; Brambilla E; Byrnes G; Scelo G; Le Calvez-Kelm F; Foll M; McKay JD; Brennan P
    EBioMedicine; 2016 Aug; 10():117-23. PubMed ID: 27377626
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.
    Punnoose EA; Atwal S; Liu W; Raja R; Fine BM; Hughes BG; Hicks RJ; Hampton GM; Amler LC; Pirzkall A; Lackner MR
    Clin Cancer Res; 2012 Apr; 18(8):2391-401. PubMed ID: 22492982
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Technical considerations for circulating tumor DNA detection in oncology.
    Franczak C; Filhine-Tresarrieu P; Gilson P; Merlin JL; Au L; Harlé A
    Expert Rev Mol Diagn; 2019 Feb; 19(2):121-135. PubMed ID: 30648442
    [TBL] [Abstract][Full Text] [Related]  

  • 60. SiNVICT: ultra-sensitive detection of single nucleotide variants and indels in circulating tumour DNA.
    Kockan C; Hach F; Sarrafi I; Bell RH; McConeghy B; Beja K; Haegert A; Wyatt AW; Volik SV; Chi KN; Collins CC; Sahinalp SC
    Bioinformatics; 2017 Jan; 33(1):26-34. PubMed ID: 27531099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.